Clinical trials: Demyelinating Disorder
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Role of High Frequency Ultrasound in Demyelinating Polyneuropathies
The use of neuroimaging in the evaluation of neuromuscular pathologies is a promising and rapidly expandinf field. Among the different imaging techniques employed, nerve ultrasound is of particular interest given it's non…
- Trial name
- NCT04978623
- Testing
- high frequency ultrasound
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Progressive Multiple Sclerosis, Depression
Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients
This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS).
- Trial name
- NCT07392879
- Testing
- Virtual Reality, Standard care
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Relapsing-remitting Multiple Sclerosis
Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis
There are two standard and a few second line treatments for RRMS. Since the disease cannot be cured by these existing treatments and all treatment options have significant limitations, there is the need to develop new treatment…
- Trial name
- RESI (NCT02364986)
- Testing
- Rebif®, Avonex
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- PD Dr. Marcus Müller
Multiple Sclerosis
Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS
The primary objective of this study is to investigate the cognitive benefits of ozanimod in individuals with Multiple Sclerosis (MS).
- Trial name
- NCT06334094
- Testing
- Ozanimod
- Where
- United States
- Sponsor
- The University of Texas at Dallas
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis
Healthy Eating and Active Living for People Living With Multiple Sclerosis (HEAL MS): A Lifestyle Program for People With Multiple Sclerosis
The goal of this clinical trial is to learn whether a structured lifestyle program can improve health and wellbeing in people living with multiple sclerosis (MS).
- Trial name
- HEAL-MS (NCT07589062)
- Testing
- Multi-Domain Lifestyle Intervention
- Where
- United Arab Emirates
- Volunteers
- 30 people
- Sponsor
- New York University Abu Dhabi
Multiple Sclerosis
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study
The Main Hypothesis of this extension trial is that among those who have successfully discontinued their DMT as part of the DISCOMS trial (i.e.
- Trial name
- NCT04754542
- Where
- 10 sites in United States
- Volunteers
- 76 people
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis
Cognitive Effects of Immunomodulatory Drugs in MS
The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications (Avonex, Copaxone, or Rebif).
- Trial name
- NCT00229502
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sharon Lynch, MD
Multiple Sclerosis
Prospective Randomized Endovascular Therapy in Multiple Sclerosis
1. To assess the safety of endovascular therapy (balloon angioplasty) for venous stenoses in MS patients with CCSVI as documented by sonographic (extracranial echocolor-Doppler (ECD) and transcranial color Doppler (TCD) 2.
- Trial name
- PREMiSe (NCT05380362)
- Testing
- Venous Angioplasty
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University at Buffalo
Malignant Brain Neoplasm, Malignant Solid Neoplasm
Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
This clinical trial studies the effect of respiratory training for enhancing brain and mental health among patients with multiple sclerosis (MS) and cancer (along with their caregivers).
- Conditions
- Malignant Brain Neoplasm, Malignant Solid Neoplasm, Multiple Sclerosis, Neuroendocrine Tumor
- Trial name
- NCT06788886
- Testing
- Biospecimen Collection, Exercise Intervention, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Multiple Sclerosis (MS), Myasthenia Gravis (MG)
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard…
- Conditions
- Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus
- Trial name
- NCT07676266
- Testing
- CD20/BCMA-directed CAR-T cells Autologous 2nd generation
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Multiple Sclerosis, Relapsing-Remitting, Vitamin D Deficiency
Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis
Vitamin D is important risk factor for developing multiple sclerosis (MS) and for disease progression. Patients with MS who had lower vitamin D levels were at increased risk for more clinical attacks and faster disease…
- Trial name
- NCT03385356
- Testing
- Vitamin D
- Where
- Slovenia
- Volunteers
- 89 people
- Sponsor
- University Medical Centre Maribor
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disease that affects the peripheral nerves. It causes progressive weakness and sensory loss in the arms and legs, which can severely limit daily…
- Trial name
- STEPS (NCT07273903)
- Where
- 2 sites in Germany
- Volunteers
- 35 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Relapsing Remitting Multiple Sclerosis
BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
The purpose of this study is to determine if BHT-3009 decreases inflammation (measured by gadolinium enhancing MRI lesions) in the brains of people with relapsing remitting multiple sclerosis.
- Trial name
- NCT00382629
- Testing
- BHT-3009 0.5 mg, BHT-3009 1.5 mg
- Volunteers
- 252 people
- Sponsor
- Bayhill Therapeutics
Multiple Sclerosis, Parkinson Disease
Biomarkers of Synaptic Damage in Multiple Sclerosis
A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit.
- Conditions
- Multiple Sclerosis, Parkinson Disease, Amyotrophic Lateral Sclerosis, Alzheimer Disease
- Trial name
- NCT03217396
- Testing
- lumbar puncture
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Neuromed IRCCS
Pelizaeus-Merzbacher Disease
Study of Human Central Nervous System (CNS) Stem Cells Transplantation in Pelizaeus-Merzbacher Disease (PMD) Subjects
The purpose of this study is to determine the safety and preliminary effectiveness of human central nervous system stem cells (HuCNS-SC®) transplantation in patients with Connatal Pelizaeus-Merzbacher Disease (PMD).
- Trial name
- NCT01005004
- Testing
- HuCNS-SC cells
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- StemCells, Inc.
Multiple Sclerosis
Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients
The investigators hypothesize that serum neurofilament-light chain (NfL) levels at baseline and decrease of the macular ganglion cell complex (GCC) thickness at one year vs.
- Trial name
- NFL OCT (NCT04860947)
- Testing
- Brain MRI, Spinal Cord MRI, Retinal imaging
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Neurocognitive Disorders, Cognitive Dysfunction
A Pilot Randomized Controlled Trial: CoINTEGRATE
The purpose of this study is to examine the feasibility of comprehensive multimodal individually tailored Cognitive Behavioral Therapy (CBT), Cognitive Rehabilitation Therapy (CRT), and modifiable lifestyle sessions.
- Conditions
- Neurocognitive Disorders, Cognitive Dysfunction, Traumatic Brain Injury, Multiple Sclerosis
- Trial name
- CoINTEGRATE (NCT05732285)
- Testing
- CRT, CBT, Modifiable lifestyle factors
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan
Multiple Sclerosis, Major Depressive Disorder
Pilot Study of the Safety and Tolerability of L-DLPFC iTBS rTMS for MDD in MS
The main purpose of this study is to investigate the safety and tolerability of intermittent Theta Burst (iTBS) repetitive transcranial magnetic stimulation (rTMS), its effectiveness in alleviating depressive symptoms as well as…
- Trial name
- NCT04621708
- Testing
- Repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Sunnybrook Health Sciences Centre
Multiple Sclerosis (Primary or Secondary Progressive Phase).
The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis
In a double-blind, placebo-controlled, parallel group trial, recombinant human erythropoietin (rhEPO) (48000 IU) treatment or placebo will be administered weekly i.v. for 24 weeks: weekly for 12 weeks and bi-weekly for 12 weeks.
- Trial name
- EPO-ProgMS (NCT01144117)
- Testing
- Erythropoietin
- Where
- Denmark
- Volunteers
- 56 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Gait Disorders, Neurologic, Urinary Incontinence, Urge
Time to be Ready to Void: a New Tool to Assess the Time Needed to Perform Micturition in Multiple Sclerosis
The aim of the study is to create a specific test to assess the global time required to go to the toilet and to perform micturition, at the moment the patient decides to urinate in multiple sclerosis population, and to assess its…
- Conditions
- Gait Disorders, Neurologic, Urinary Incontinence, Urge, Multiple Sclerosis
- Trial name
- NCT04024085
- Testing
- completion of the test created Time to be Ready to Void
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Gérard Amarenco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.